Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Update !!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Post by HighSkies2019on Mar 03, 2022 9:55am
109 Views
Post# 34478708

Update !!!

Update !!!Why isn't Rob giving an update ...last nr Feb 22 ....supposedly they as in Clas was to provide more info...Bailey if it wasn't that big of a deal it should have been processed and completed...a phase 1 that was suppose to start Aug 2021 with a phase 1 finish by yr end 2021.....everything again was delayed turned into phase 1 completed by Q1 and yet here we are Mar 3 2022 ....phase 1 not even started or news with a start date...how long does Bob expect investors to hang on.....looks like B warrants have slim chance to cash out in April...all lost money for investors and company .... why is Rob's shares still listed under Kly....and for the PP done in Oct 2019 with warrants to expire in Aug 2022 ... has this company ever excercised any warrsnts in the history of all this co. name changes....seems like everyone is happy to accept this...no not whining or complaining ....just doesn't look good glta
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities